MPT Product Development Database

This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
Hormonal/Non-HormonalDelivery RouteDelivery MethodDevelopment Stage
       
IndicationProduct DeveloperProduct Sponsor/FundingActive Ingredient
       
Key Word Search   
       

23 product(s) found



TAF / Elvitegravir Topical Insert

MPT in Development

Development Stage:
Clinical – Phase 1 Trial (C1)
Hormonal/Non-Hormonal:
X
Delivery Route & Method:
Topical - Fast Dissolve Insert – Vaginal, Rectal
Mechanism of Action:
Nucleoside analogue reverse transcriptase inhibitor (NRTI); Integrase strand-transfer inhibitor
Developer:
  • CONRAD
  • Funding:
  • The Bill & Melinda Gates Foundation
  • National Institutes of Health (NIH)
  • U.S. Agency for International Development (USAID)
  • Funding Mechanism:
    USAID: Cooperative agreement, interagency agreement [USAID-CDC];
    NIH: MTN
    Past Funding:
    Bill & Melinda Gates Foundation
    Active Ingredient:
  • Elvitegravir
  • Tenofovir Alafenamide (TAF)
  • Product Indications:
  • HIV
  • HSV-2
  • Description:
    Solid, tablet-like dosage form for dual-compartment (vaginal or rectal) on-demand use. Studies in non-human primates demonstrate proof-of-concept that a single TAF/EVG insert dosed vaginally several hours either before or after SHIV exposure provides strong protection. A Phase I study to assess safety, pharmacokinetics, and pharmacodynamics of the TAF/EVG insert administered vaginally (CONRAD A18-146) was completed in early 2019; dissemination of results is planned mid-2020. A Phase 1 study to assess rectal administration of the TAF/EVG insert (MTN-039) was initiated in late 2019 and is ongoing. A placebo form of this insert was also evaluated in two international, multi-site acceptability studies, including the Quatro study, comparing four vaginal dosage forms in African women, and the MTN-035 (DESIRE) study, comparing three different rectal dosage forms.
    IMPT Secretariat
    1750 Howe Avenue, Suite 550
    Sacramento, CA 95825
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    © Copyright 2019, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.

    The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, an organization dedicated to advancing the comprehensive sexual and reproductive health of women and girls worldwide. CAMI Health is housed at the Public Health Institute (PHI).

    This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
    PEPFAR USAID PHI CAMI Health